Volume 5, Issue 2, March 2017, Page: 9-13
BRCA1 Promoter Hypermethylationas an Early Diagnostic Tool for Breast Cancer
Tehseen Hassan, Department of Biochemistry, Govt. Medical College Srinagar, Jammu & Kashmir, India
Showkat Ahmad Bhat, Department of Biochemistry, Govt. Medical College Srinagar, Jammu & Kashmir, India
Sabhiya Majid, Department of Biochemistry, Govt. Medical College Srinagar, Jammu & Kashmir, India
Manzoor R. Mir, Division of Vety Biochemistry, Faculty of Veterinary Sciences, SKUAST-K, Jammu & Kashmir, India
Purnima Shrivastava, Director Research Bhagwant University, Sikar Road Ajmer, Rajasthan, India
Received: May 1, 2017;       Accepted: May 24, 2017;       Published: Jun. 23, 2017
DOI: 10.11648/j.crj.20170502.11      View  1985      Downloads  176
Abstract
Background: Breast cancer is the second most common cancer among women after cervical cancer. As Cancer development and progression is dictated by chain of alterations in genes. Over the past few years, the Kashmir valley has witnessed a tremendous increase in the incidence of breast cancer in its unexplored ethnic population. The aim of present study was to find out the role of Promoter Hypermethylation of BRCA1 gene in Breast cancer patients. Material Methods: The DNA was extracted from all the samples and was modified using bisulphite modification kit. Methylation-specific polymerase chain reaction was used for the analysis of the promoter hypermethylation status of BRCA1 gene. Results: The epigenetic analysis revealed that unlike other high risk regions, Kashmiri population has a different promoterhypermethylation profile of BRCA1 gene as 68% of the cases showed BRCA1 promoter hypermethylation in comparison to 20% of the normal cases, the association of promoter hypermethylation with breast cancer and normal cases was found to be significant (P=0.0006). The frequency of BRCA1 promoter hypermethylation was found to be certainly higher in Stage III/IV (75%) compared to Stage I/ II (62%) but the difference was not statistically significant(P =0.0674). The frequency of promoter methylation was foundhigher (77.1%) in age group above 60- years) than ages below 60 years. Conclusion: These results suggest that BRCA1 aberrant promoter hypermethylation in Kashmiri population contributes to the process of carcinogenesis in breast cancer and is reportedly one of the commonest epigenetic changes in the development of breast cancer.
Keywords
Breast Cancer, BRCA1, Hypermethylation, Bisulphite Treatment
To cite this article
Tehseen Hassan, Showkat Ahmad Bhat, Sabhiya Majid, Manzoor R. Mir, Purnima Shrivastava, BRCA1 Promoter Hypermethylationas an Early Diagnostic Tool for Breast Cancer, Cancer Research Journal. Vol. 5, No. 2, 2017, pp. 9-13. doi: 10.11648/j.crj.20170502.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
AurelieCatteau and Joanna R. Morris.Cancer biology. 2002, 12: 359–371.
[2]
Castilla LH, Couch FJ, Erdos MR, Hoskins KF, Calzone K, Garber JE. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. Nat Genet. 1994; 8:387–91.
[3]
Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene. 1999; 18:1957–65.
[4]
Easton D. Breast cancer genes, what are the real risks? Nat Genet. 1997; 16:210–1.
[5]
Esteller M (2002). CpG island hypermethylation and tumor suppressor genes:a booming present, a brighter future. Oncogene. 2002; 21: 5427-40.
[6]
Esteller M., Epigenetics in cancer,N. Engl. J. Med. 2008; 3 (58): 1148–1159.
[7]
Fang WJ, Zheng Y, Wu LM, et al. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Asian Pac J Cancer 2012.
[8]
Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. Confirmation of BRCAI by analysis of germline mutations. Nature genetics. 1994; 8: 399-404.
[9]
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100 (1): 57-70.
[10]
Hora Loghmani, MehrdadNoruzinia, Hossein Abdul-Tehrani, et al. Association of estrogen receptors’ promoter methylation and clinicopathological characteristics in Iranian patients with breast cancer. Molecular and Biochemical diagnosis (MBD). 2014; 1(1): 21-33.
[11]
Knudson AG. Hereditary cancer, oncogenes, and antioncogenes. Cancer Research,. 1985; 45(4): 1437-1443.
[12]
Magdinier F, Ribieras S, Lenoir GM, Frappart L, Dante R. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene.1998; 17 (24): 3169-76.
[13]
Niwa Y, Oyama T, Nakajima T. BRCA1 expression status in relation to DNA methylation of the BRCA1 promoter region in sporadic breast cancers. Cancer Science. 2000; 91 (5): 519-26.
[14]
Parvin JD. Overview of history and progress in BRCA1 research: the first BRCA1 decade. Cancer biology & therapy. 2004; 3 (6): 505-8.
[15]
Phuong Kim Truong, ThuanDuc Lao, Thao Phuong Thi Doan, Thuy Ai Huyen Le1. BRCA1 Promoter Hypermethylation Signature for Early Detection of Breast Cancer in the Vietnamese Population. Asian Pac J Cancer Prev. 2014; 15 (22): 9607-9610.
[16]
Phuong Kim Truong, ThuanDuc Lao1, Thao Phuong Thi Doan, et al. BRCA1 Promoter Hypermethylation Signature for Early Detection of Breast Cancer in the Vietnamese Population. Asian Pac J Cancer Prev. 2014; 5 (22): 9607-9610.
[17]
Ramezani F, Salami S, Omrani MD, Maleki D. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis. Asian Pac J Cancer Prev. 2012; 13: 451-7.
[18]
Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis. 2000; 21 (9): 1761-5.
[19]
Showkat Ahmad Bhat, Manzoor R Mir, Sabhiya Majid. Serum lipid profile of breast cancer patients in Kashmir. J Invest Biochem. 2013; 2 (1): 26-31.
[20]
Tapia T, Smalley SV, Kohen P, et al. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. Epigenetics. 2008; 3, 157-63.
[21]
Wernberg JA, Yap J, Murekeyisoni C, Mashtare T, Wilding GE. Multiple primary tumors in men with breast cancer review. J SurgOncol. 2009; 99: 16-9.
Browse journals by subject